M&A Deal Summary |
|
---|---|
Date | 2020-11-16 |
Target | AMAG Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Covis Pharma Sàrl |
Deal Type | Add-on Acquisition |
Deal Value | 647M USD |
Advisor(s) | Goldman Sachs (Financial) Goodwin Procter (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Covis Pharma is a specialty pharmaceutical company providing therapeutic solutions to patients. Covis markets a portfolio of U.S. prescription products through its U.S. sales and distribution affiliate, Covis Pharmaceuticals, Inc. which is headquartered in Cary, North Carolina.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 2 of 2 |
Type (Add-on Acquisition) | 1 of 1 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2020) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2018-11-06 |
AstraZeneca - Alvesco Omnaris and Zetonna Business
London, United Kingdom AstraZeneca Plc - Alvesco, Omnaris and Zetonna Business used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines. |
Buy | $350M |